Selected research
Industry Growth & Trends
Global Anti-VEGF Therapy for Cancer Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Anti-VEGF Therapy for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-VEGF Therapy for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Anti-VEGF Therapy for Cancer market include Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Sanofi, Roche, Pfizer, Novartis, Janssen Biotech, Exelixis and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Anti-VEGF Therapy for Cancer market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anti-VEGF Therapy for Cancer market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-VEGF Therapy for Cancer market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-VEGF Therapy for Cancer.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Anti-VEGF Therapy for Cancer market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anti-VEGF Therapy for Cancer Market by Company
Chia Tai Tianqing
Jiangsu Hengrui Pharmaceuticals
Sanofi
Roche
Pfizer
Novartis
Janssen Biotech
Exelixis
Eli Lilly
Eisai
Boehringer Ingelheim
Bayer
AstraZeneca
Anti-VEGF Therapy for Cancer Segment by Type
VEGF Inhibitors
VEGFR Inhibitors
Anti-VEGF Therapy for Cancer Segment by Application
Non-small Cell Lung Cancer
Cervical Cancer
Colorectal Cancer
Renal Cell Carcinoma
Medullary Thyroid Cancer
Other
Anti-VEGF Therapy for Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapy for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti-VEGF Therapy for Cancer companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- VEGF Inhibitors
- VEGFR Inhibitors
Applications
- Non-small Cell Lung Cancer
- Cervical Cancer
- Colorectal Cancer
- Renal Cell Carcinoma
- Medullary Thyroid Cancer
- Other
Companies covered
- Chia Tai Tianqing
- Jiangsu Hengrui Pharmaceuticals
- Sanofi
- Roche
- Pfizer
- Novartis
- Janssen Biotech
- Exelixis
- Eli Lilly
- Eisai
- Boehringer Ingelheim
- Bayer
- AstraZeneca
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Anti-VEGF Therapy for Cancer Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Anti-VEGF Therapy for Cancer Market Size by Region (2021-2032)
- 1.4.1 Global Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026)
- 1.4.2 Global Anti-VEGF Therapy for Cancer Market Size by Region (2027-2032)
- 1.5 Key Regions Anti-VEGF Therapy for Cancer Market Size (2021-2032)
- 1.5.1 North America Anti-VEGF Therapy for Cancer Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Anti-VEGF Therapy for Cancer Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size Growth Rate (2021-2032)
- 1.5.4 South America Anti-VEGF Therapy for Cancer Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Growth Rate (2021-2032)
2 Anti-VEGF Therapy for Cancer Market by Type
- 2.1 Type Introduction
- 2.1.1 VEGF Inhibitors
- 2.1.2 VEGFR Inhibitors
- 2.2 Global Anti-VEGF Therapy for Cancer Market Size by Type
- 2.2.1 Global Anti-VEGF Therapy for Cancer Market Size Overview by Type (2021-2032)
- 2.2.2 Global Anti-VEGF Therapy for Cancer Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Anti-VEGF Therapy for Cancer Market Size Forecasted by Type (2027-2032)
- 2.3 Global Anti-VEGF Therapy for Cancer Market Size by Regions
- 2.3.1 North America Anti-VEGF Therapy for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Anti-VEGF Therapy for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Anti-VEGF Therapy for Cancer Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Anti-VEGF Therapy for Cancer Market Size Breakdown by Type (2021-2026)
3 Anti-VEGF Therapy for Cancer Market by Application
- 3.1 Type Introduction
- 3.1.1 Non-small Cell Lung Cancer
- 3.1.2 Cervical Cancer
- 3.1.3 Colorectal Cancer
- 3.1.4 Renal Cell Carcinoma
- 3.1.5 Medullary Thyroid Cancer
- 3.1.6 Other
- 3.2 Global Anti-VEGF Therapy for Cancer Market Size by Application
- 3.2.1 Global Anti-VEGF Therapy for Cancer Market Size Overview by Application (2021-2032)
- 3.2.2 Global Anti-VEGF Therapy for Cancer Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Anti-VEGF Therapy for Cancer Market Size Forecasted by Application (2027-2032)
- 3.3 Global Anti-VEGF Therapy for Cancer Market Size by Regions
- 3.3.1 North America Anti-VEGF Therapy for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Anti-VEGF Therapy for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Anti-VEGF Therapy for Cancer Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Anti-VEGF Therapy for Cancer Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Anti-VEGF Therapy for Cancer Industry Trends
- 4.2 Anti-VEGF Therapy for Cancer Industry Drivers
- 4.3 Anti-VEGF Therapy for Cancer Industry Opportunities and Challenges
- 4.4 Anti-VEGF Therapy for Cancer Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Anti-VEGF Therapy for Cancer Revenue (2021-2026)
- 5.2 Global Anti-VEGF Therapy for Cancer Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Anti-VEGF Therapy for Cancer Key Company Headquarters & Area Served
- 5.4 Global Anti-VEGF Therapy for Cancer Company, Product Type & Application
- 5.5 Global Anti-VEGF Therapy for Cancer Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Anti-VEGF Therapy for Cancer Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Anti-VEGF Therapy for Cancer Players Market Share by Revenue in 2025
- 5.6.3 2025 Anti-VEGF Therapy for Cancer Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Chia Tai Tianqing
- 6.1.1 Chia Tai Tianqing Company Information
- 6.1.2 Chia Tai Tianqing Business Overview
- 6.1.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio
- 6.1.5 Chia Tai Tianqing Recent Developments
- 6.2 Jiangsu Hengrui Pharmaceuticals
- 6.2.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 6.2.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 6.2.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio
- 6.2.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sanofi Anti-VEGF Therapy for Cancer Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Roche
- 6.4.1 Roche Company Information
- 6.4.2 Roche Business Overview
- 6.4.3 Roche Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Roche Anti-VEGF Therapy for Cancer Product Portfolio
- 6.4.5 Roche Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Anti-VEGF Therapy for Cancer Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Novartis
- 6.6.1 Novartis Company Information
- 6.6.2 Novartis Business Overview
- 6.6.3 Novartis Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Novartis Anti-VEGF Therapy for Cancer Product Portfolio
- 6.6.5 Novartis Recent Developments
- 6.7 Janssen Biotech
- 6.7.1 Janssen Biotech Company Information
- 6.7.2 Janssen Biotech Business Overview
- 6.7.3 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio
- 6.7.5 Janssen Biotech Recent Developments
- 6.8 Exelixis
- 6.8.1 Exelixis Company Information
- 6.8.2 Exelixis Business Overview
- 6.8.3 Exelixis Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Exelixis Anti-VEGF Therapy for Cancer Product Portfolio
- 6.8.5 Exelixis Recent Developments
- 6.9 Eli Lilly
- 6.9.1 Eli Lilly Company Information
- 6.9.2 Eli Lilly Business Overview
- 6.9.3 Eli Lilly Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio
- 6.9.5 Eli Lilly Recent Developments
- 6.10 Eisai
- 6.10.1 Eisai Company Information
- 6.10.2 Eisai Business Overview
- 6.10.3 Eisai Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Eisai Anti-VEGF Therapy for Cancer Product Portfolio
- 6.10.5 Eisai Recent Developments
- 6.11 Boehringer Ingelheim
- 6.11.1 Boehringer Ingelheim Company Information
- 6.11.2 Boehringer Ingelheim Business Overview
- 6.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio
- 6.11.5 Boehringer Ingelheim Recent Developments
- 6.12 Bayer
- 6.12.1 Bayer Company Information
- 6.12.2 Bayer Business Overview
- 6.12.3 Bayer Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Bayer Anti-VEGF Therapy for Cancer Product Portfolio
- 6.12.5 Bayer Recent Developments
- 6.13 AstraZeneca
- 6.13.1 AstraZeneca Company Information
- 6.13.2 AstraZeneca Business Overview
- 6.13.3 AstraZeneca Anti-VEGF Therapy for Cancer Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio
- 6.13.5 AstraZeneca Recent Developments
7 North America
- 7.1 North America Anti-VEGF Therapy for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 7.3 North America Anti-VEGF Therapy for Cancer Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Anti-VEGF Therapy for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 8.3 Europe Anti-VEGF Therapy for Cancer Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Anti-VEGF Therapy for Cancer Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Anti-VEGF Therapy for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 10.3 South America Anti-VEGF Therapy for Cancer Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst